A New Way to Establish Cause and Effect in Epidemiology?

A technique called Mendelian randomization is overturning the conclusions of observational studies in public health. But researchers question whether the method can overcome its fundamental limitations.

Written byRachael Moeller Gorman
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

ABOVE: © ISTOCK.COM, ARTHOBBIT

At the turn of the 21st century, University of Bristol epidemiologist George Davey Smith was growing dissatisfied with his field. “I’ve been working in epidemiology for a very long time,” he says. “And I was disillusioned with the conventional approaches to try to establish cause and effect in observational epidemiology.”

Confounding factors plague observational studies, which examine populations of people to identify correlations between environmental conditions or lifestyle factors and disease and therefore cannot draw conclusions about a disease’s cause. Highlighting the approach’s limitations is the fact that randomized controlled trials, widely considered the gold standard for medical evidence, have failed to confirm many observational results or translate them into interventions. Observational epidemiological studies, Davey Smith says, were “obviously getting things wrong.”

So in 2003, he wrote a paper that outlined how to reframe an observational study as a natural experiment by incorporating a dash of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After earning a bachelor’s degree in biology and neuroscience from Williams College, Rachael spent two years studying the tiny C. elegans worm as a lab tech at Massachusetts General Hospital/Harvard University. She then returned to school to get a master’s degree in environmental studies from Brown University, and subsequently worked as an intern at Scientific AmericanDiscover magazine, and the Annals of Improbable Research, the originators of the yearly Ig Nobel prizes. She now freelances for both scientific and lay publications, and loves telling the stories behind the science. Find her at rachaelgorman.com or on Instagram @rachaelmoellergorman.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies